Organigram Global (STU:0OG) Piotroski F-Score: 4 (As of Jun. 26, 2026) — Near Median


STU:0OG Organigram Global Inc STU:0OG
60 GF Score
Price €0.82
GF Value €1.46
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Organigram Global Piotroski F-Score?

Organigram Global STU:0OG -0.85% 60 Piotroski F-Score is 4 as of Jun. 26, 2026, which is at its 10-year median of 4.00. GuruFocus rates STU:0OG with a GF Score™ of 60/100 and a GF Value™ of €1.46 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 981 Drug Manufacturers companies, Organigram Global ranks worse than 61.06% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Organigram Global has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Organigram Global's Piotroski F-Score or its related term are showing as below:

STU:0OG' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 7
Current: 4

During the past 13 years, the highest Piotroski F-Score of Organigram Global was 7. The lowest was 1. And the median was 4.

Organigram Global  (STU:0OG) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Organigram Global Piotroski F-Score Related Terms


Organigram Global Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Organigram Global's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organigram Global Piotroski F-Score Chart

Organigram Global Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Sep24 Sep25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 5.00 4.00 7.00 4.00

Organigram Global Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 5.00 4.00 5.00 4.00

STU:0OG vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Organigram Global's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organigram Global Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organigram Global's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Organigram Global's Piotroski F-Score falls into.


STU:0OG
60GF Score
Organigram Global Inc STU:0OG
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -3.992 + -23.381 + 12.362 + -0.581 = €-15.6 Mil.
Cash Flow from Operations was 9.278 + -0.894 + -9.913 + -4.262 = €-5.8 Mil.
Revenue was 44.905 + 49.307 + 39.334 + 37.698 = €171.2 Mil.
Gross Profit was 16.585 + 19.608 + 14.433 + 10.344 = €61.0 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(346.587 + 358.151 + 346.251 + 328.521 + 328.67) / 5 = €341.636 Mil.
Total Assets at the begining of this year (Mar25) was €346.6 Mil.
Long-Term Debt & Capital Lease Obligation was €4.6 Mil.
Total Current Assets was €157.7 Mil.
Total Current Liabilities was €56.0 Mil.
Net Income was 1.91 + -3.614 + -15.388 + 27.356 = €10.3 Mil.

Revenue was 27.833 + 29.73 + 28.643 + 42.268 = €128.5 Mil.
Gross Profit was 9.495 + 11.451 + 9.26 + 11.867 = €42.1 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(225.499 + 240.468 + 271.284 + 321.22 + 346.587) / 5 = €281.0116 Mil.
Total Assets at the begining of last year (Mar24) was €225.5 Mil.
Long-Term Debt & Capital Lease Obligation was €5.3 Mil.
Total Current Assets was €166.6 Mil.
Total Current Liabilities was €48.7 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Organigram Global's current Net Income (TTM) was -15.6. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Organigram Global's current Cash Flow from Operations (TTM) was -5.8. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-15.592/346.587
=-0.04498726

ROA (Last Year)=Net Income/Total Assets (Mar24)
=10.264/225.499
=0.04551683

Organigram Global's return on assets of this year was -0.04498726. Organigram Global's return on assets of last year was 0.04551683. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Organigram Global's current Net Income (TTM) was -15.6. Organigram Global's current Cash Flow from Operations (TTM) was -5.8. ==> -5.8 > -15.6 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=4.565/341.636
=0.01336217

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=5.304/281.0116
=0.01887467

Organigram Global's gearing of this year was 0.01336217. Organigram Global's gearing of last year was 0.01887467. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=157.671/55.951
=2.81801934

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=166.561/48.726
=3.41831876

Organigram Global's current ratio of this year was 2.81801934. Organigram Global's current ratio of last year was 3.41831876. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Organigram Global's number of shares in issue this year was 131.571. Organigram Global's number of shares in issue last year was 133.509. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=60.97/171.244
=0.35604167

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=42.073/128.474
=0.3274826

Organigram Global's gross margin of this year was 0.35604167. Organigram Global's gross margin of last year was 0.3274826. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=171.244/346.587
=0.49408662

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=128.474/225.499
=0.56973202

Organigram Global's asset turnover of this year was 0.49408662. Organigram Global's asset turnover of last year was 0.56973202. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+1+1+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Organigram Global has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Organigram Global (STU:0OG) has a Piotroski F-Score of 4 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Organigram Global and its competitors. This is near median its historical median of 4.00. Over the past decade, Organigram Global's Piotroski F-Score has ranged from 1.00 to 7.00. According to the industry distribution chart, Organigram Global ranks #599 out of 981 companies in the Drug Manufacturers industry, placing it in the top 61.1%.
Is Organigram Global's Piotroski F-Score too high?
Organigram Global's current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Organigram Global's value of 4 is 20% below this industry median. Based on the distribution chart, Organigram Global ranks #599 out of 981 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Organigram Global has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Organigram Global's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Organigram Global ranks #599 out of 981 companies for Piotroski F-Score. This places Organigram Global in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Organigram Global's value of 4 is 20% below this benchmark. Historically, Organigram Global's own Piotroski F-Score has ranged from 1.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Organigram Global has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organigram Global's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Organigram Global and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organigram Global's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organigram Global stock overvalued right now?
Based on GuruFocus' analysis, Organigram Global (STU:0OG) is currently considered Possible Value Trap. The stock's GF Value™ is €1.46, compared to a current price of €0.82 — trading 44.1% below its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 20% below the Drug Manufacturers industry median of 5.00. Organigram Global's overall GF Score™ is 60/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Organigram Global (STU:0OG), the current Piotroski F-Score is 4 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organigram Global (STU:0OG) Overvalued in 2026?

Based on GuruFocus' analysis, Organigram Global stock appears to be undervalued. The current stock price of €0.82 is trading 44.1% below its estimated GF Value™ of €1.46. GuruFocus considers Organigram Global to be Possible Value Trap.

Key valuation signals for STU:0OG:

  • Piotroski F-Score: 4 (near median its 10-year median of 4.00)
  • GF Value™: €1.46 vs. price of €0.82 (44.1% below fair value)
  • GF Score™: 60/100 with 1 warning sign
  • Industry Position: 20% below the Drug Manufacturers median (#599 of 981)

No single metric tells the full story. See the STU:0OG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Organigram Global Business Description

Other Exchanges OGI:USAOGI:Canada
Address 145 King Street West, Suite 1400, Toronto, ON, CAN, M5H 1J8
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
60GF Score

Get the complete analysis for STU:0OG

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.82
Price
€1.46
GF Value